A carregar...
Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant
Lemborexant, a dual orexin receptor antagonist, is approved in the United States, Japan, and Canada for the treatment of insomnia in adults. This phase I, multicenter, open‐label, parallel‐group study assessed the impact of mild or moderate hepatic impairment (HI) on lemborexant pharmacokinetics and...
Na minha lista:
| Publicado no: | Pharmacol Res Perspect |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8023329/ https://ncbi.nlm.nih.gov/pubmed/33822479 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.758 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|